234 related articles for article (PubMed ID: 25876877)
1. The ErbB3-binding protein EBP1 modulates lapatinib sensitivity in prostate cancer cells.
Awasthi S; Ezelle H; Hassel BA; Hamburger AW
Mol Cell Biochem; 2015 Jul; 405(1-2):177-86. PubMed ID: 25876877
[TBL] [Abstract][Full Text] [Related]
2. EBP1, an ErbB3-binding protein, is decreased in prostate cancer and implicated in hormone resistance.
Zhang Y; Linn D; Liu Z; Melamed J; Tavora F; Young CY; Burger AM; Hamburger AW
Mol Cancer Ther; 2008 Oct; 7(10):3176-86. PubMed ID: 18852121
[TBL] [Abstract][Full Text] [Related]
3. The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells.
Zhang Y; Wang XW; Jelovac D; Nakanishi T; Yu MH; Akinmade D; Goloubeva O; Ross DD; Brodie A; Hamburger AW
Proc Natl Acad Sci U S A; 2005 Jul; 102(28):9890-5. PubMed ID: 15994225
[TBL] [Abstract][Full Text] [Related]
4. Specificity and heregulin regulation of Ebp1 (ErbB3 binding protein 1) mediated repression of androgen receptor signalling.
Zhang Y; Hamburger AW
Br J Cancer; 2005 Jan; 92(1):140-6. PubMed ID: 15583694
[TBL] [Abstract][Full Text] [Related]
5. Repression of androgen receptor mediated transcription by the ErbB-3 binding protein, Ebp1.
Zhang Y; Fondell JD; Wang Q; Xia X; Cheng A; Lu ML; Hamburger AW
Oncogene; 2002 Aug; 21(36):5609-18. PubMed ID: 12165860
[TBL] [Abstract][Full Text] [Related]
6. Lapatinib-resistant cancer cells possessing epithelial cancer stem cell properties develop sensitivity during sphere formation by activation of the ErbB/AKT/cyclin D2 pathway.
Ohnishi Y; Yasui H; Kakudo K; Nozaki M
Oncol Rep; 2016 Nov; 36(5):3058-3064. PubMed ID: 27633099
[TBL] [Abstract][Full Text] [Related]
7. The ErbB3 binding protein EBP1 regulates ErbB2 protein levels and tamoxifen sensitivity in breast cancer cells.
Lu Y; Zhou H; Chen W; Zhang Y; Hamburger AW
Breast Cancer Res Treat; 2011 Feb; 126(1):27-36. PubMed ID: 20379846
[TBL] [Abstract][Full Text] [Related]
8. Heregulin negatively regulates transcription of ErbB2/3 receptors via an AKT-mediated pathway.
Awasthi S; Hamburger AW
J Cell Physiol; 2014 Nov; 229(11):1831-41. PubMed ID: 24692179
[TBL] [Abstract][Full Text] [Related]
9. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
[TBL] [Abstract][Full Text] [Related]
10. EBP1 inhibits translation of androgen receptor mRNA in castration resistant prostate cancer cells.
Zhou H; Zhang Y; Hamburger AW
Anticancer Res; 2011 Oct; 31(10):3129-35. PubMed ID: 21965718
[TBL] [Abstract][Full Text] [Related]
11. Post-transcriptional regulation of androgen receptor mRNA by an ErbB3 binding protein 1 in prostate cancer.
Zhou H; Mazan-Mamczarz K; Martindale JL; Barker A; Liu Z; Gorospe M; Leedman PJ; Gartenhaus RB; Hamburger AW; Zhang Y
Nucleic Acids Res; 2010 Jun; 38(11):3619-31. PubMed ID: 20159994
[TBL] [Abstract][Full Text] [Related]
12. EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells.
Grøvdal LM; Kim J; Holst MR; Knudsen SL; Grandal MV; van Deurs B
Cell Signal; 2012 Jan; 24(1):296-301. PubMed ID: 21951604
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of heregulin mediated MCF-7 breast cancer cell growth by the ErbB3 binding protein EBP1.
Zhang Y; Akinmade D; Hamburger AW
Cancer Lett; 2008 Jul; 265(2):298-306. PubMed ID: 18355957
[TBL] [Abstract][Full Text] [Related]
14. ErbB3-binding protein EBP1 decreases ErbB2 levels via a transcriptional mechanism.
Ghosh A; Awasthi S; Hamburger AW
Oncol Rep; 2013 Mar; 29(3):1161-6. PubMed ID: 23242156
[TBL] [Abstract][Full Text] [Related]
15. ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor.
Juliachs M; Castillo-Ávila W; Vidal A; Piulats JM; Garcia Del Muro X; Condom E; Hernández-Losa J; Teixidó C; Pandiella A; Graupera M; Casanovas O; Germà JR; Villanueva A; Viñals F
Int J Cancer; 2013 Jul; 133(1):235-46. PubMed ID: 23292912
[TBL] [Abstract][Full Text] [Related]
16. The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells.
Lyu H; Yang XH; Edgerton SM; Thor AD; Wu X; He Z; Liu B
Oncotarget; 2016 Jan; 7(3):2921-35. PubMed ID: 26621843
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic targeting of multiple signaling pathways in malignant pleural mesothelioma.
Mukohara T; Civiello G; Johnson BE; Janne PA
Oncology; 2005; 68(4-6):500-10. PubMed ID: 16020981
[TBL] [Abstract][Full Text] [Related]
18. The expression and prognostic role of EBP1 and relationship with AR in HER2+ breast cancer.
Liu J; Xu C; Xu D; Cao L; Xue H; Meng Q; Niu Y
Virchows Arch; 2020 Aug; 477(2):279-289. PubMed ID: 32086588
[TBL] [Abstract][Full Text] [Related]
19. Regulation of tamoxifen sensitivity by a PAK1-EBP1 signalling pathway in breast cancer.
Ghosh A; Awasthi S; Peterson JR; Hamburger AW
Br J Cancer; 2013 Feb; 108(3):557-63. PubMed ID: 23361053
[TBL] [Abstract][Full Text] [Related]
20. The role of ErbB3 and its binding partners in breast cancer progression and resistance to hormone and tyrosine kinase directed therapies.
Hamburger AW
J Mammary Gland Biol Neoplasia; 2008 Jun; 13(2):225-33. PubMed ID: 18425425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
